Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

API Manufacturing: SOP for Risk-Based Inspection Planning – V 2.0

Posted on By

API Manufacturing: SOP for Risk-Based Inspection Planning – V 2.0

Standard Operating Procedure for Risk-Based Inspection Planning in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/192/2025
Supersedes SOP/API/192/2022
Page No. Page 1 of 16
Issue Date 14/04/2025
Effective Date 16/04/2025
Review Date 14/04/2026

1. Purpose

To define a standardized approach for planning inspections based on risk levels associated with materials, equipment, processes, and systems within the API manufacturing facility, thereby ensuring effective monitoring and compliance in line with ICH Q9 and cGMP requirements.

2. Scope

This SOP is applicable to the Quality Assurance (QA) team responsible for internal inspections, audits, and monitoring activities

across various departments involved in API manufacturing. It covers routine inspections, targeted risk-based assessments, and trend-based inspections.

3. Responsibilities

  • QA Team: Conducts risk assessment, prepares inspection calendar, and performs inspections.
  • Department Heads: Cooperate during inspections, provide required records, and implement corrective actions.
  • QA Manager: Reviews risk scores and inspection schedules, approves plans, and ensures follow-up.

4. Accountability

The Head of Quality Assurance is accountable for approving the risk-based inspection plan and ensuring effective execution of the inspection strategy as per regulatory and quality system requirements.

See also  API Manufacturing: SOP for Operation of FTIR Spectrometer - V 2.0

5. Procedure

5.1 Preparation of Inspection Calendar

  1. QA shall prepare an Annual Risk-Based Inspection Calendar (Annexure-1) by December for the next calendar year.
  2. The calendar shall consider:
    • Risk priority of systems/processes
    • Past inspection findings
    • Criticality of operations
    • Changes introduced or deviations reported

5.2 Risk Assessment Methodology

  1. Each process, area, or system shall be assessed using the Risk Scoring Template (Annexure-2) based on:
    • Severity (S): Potential impact on product quality or compliance
    • Occurrence (O): Likelihood of failure or deviation
    • Detection (D): Probability of detecting a failure before release
  2. Risk Priority Number (RPN) = S × O × D
  3. Risk levels shall be categorized as:
    • High: RPN ≥ 150
    • Medium: 75 ≤ RPN < 150
    • Low: RPN < 75

5.3 Inspection Planning and Frequency

  1. High-risk areas – Inspect at least once per quarter
  2. Medium-risk areas – Inspect once in six months
  3. Low-risk areas – Inspect once annually
  4. All inspections shall be unannounced to promote preparedness and routine compliance.

5.4 Execution of Inspection

  1. QA shall issue a Risk-Based Inspection Checklist (Annexure-3) tailored for the area/process being reviewed.
  2. Inspectors shall review:
    • Compliance with SOPs
    • Housekeeping and documentation practices
    • Condition of equipment and infrastructure
    • In-process control and data recording
  3. Observations shall be recorded in the Inspection Observation Log (Annexure-4).
See also  API Manufacturing: SOP for Change Control Request Evaluation and Implementation - V 2.0

5.5 Reporting and CAPA

  1. Post-inspection, QA shall prepare a Risk-Based Inspection Report (Annexure-5) within 5 working days.
  2. Departments shall respond with CAPA within 10 working days using the CAPA Response Form (Annexure-6).
  3. QA shall review CAPA implementation and close the report formally.

5.6 Trending and Review

  1. All RPN scores and findings shall be reviewed quarterly for trend identification using the Inspection Trending Log (Annexure-7).
  2. Emerging trends or repetitive findings may trigger reclassification of risk and increase in inspection frequency.

6. Abbreviations

  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • RPN: Risk Priority Number
  • SOP: Standard Operating Procedure
  • ICH: International Council for Harmonisation

7. Documents

  1. Annual Risk-Based Inspection Calendar (Annexure-1)
  2. Risk Scoring Template (Annexure-2)
  3. Risk-Based Inspection Checklist (Annexure-3)
  4. Inspection Observation Log (Annexure-4)
  5. Inspection Report Template (Annexure-5)
  6. CAPA Response Form (Annexure-6)
  7. Inspection Trending Log (Annexure-7)

8. References

  • ICH Q9 – Quality Risk Management
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – Current Good Manufacturing Practice
  • EU GMP Chapter 9 – Self Inspection

See also  API Manufacturing: SOP for Use of Activated Carbon in Recovery Process - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Annual Risk-Based Inspection Calendar

Area Risk Level Planned Inspection Frequency Responsible
API Synthesis Room High Quarterly QA

Annexure-2: Risk Scoring Template

Parameter Score (1-10) Remarks
Severity 8 Critical process step
Occurrence 7 Previous deviation reported
Detection 5 Moderate controls in place
RPN 280

Annexure-3: Risk-Based Inspection Checklist

Item Status (Y/N) Comments
Equipment Calibration Verified Yes Compliant
Area Cleanliness No Dust observed on panels

Annexure-4: Inspection Observation Log

Date Area Observation Category Inspector
12/04/2025 Drying Room Unauthorized tool present Major QA Executive

Annexure-5: Inspection Report Template

Inspection Date Area Summary Inspector
13/04/2025 Solvent Recovery 2 minor, 1 major observation QA

Annexure-6: CAPA Response Form

Observation No. CAPA Description Responsible Target Date
OBS-2025-12 Replace damaged hose line Maintenance 20/04/2025

Annexure-7: Inspection Trending Log

Month Area Observation Count Repetitive Observations Trend
March 2025 Granulation 4 2 Stable

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Release New SOP QA Head
14/04/2025 2.0 Integrated Risk Scoring and RPN classification ICH Q9 Alignment QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Aerosol: SOP for Conducting Packaging Line Validation – V 2.0
Next Post: SOP for Managing Regulatory Submissions for CE Marking

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version